Rx00091 - Duloxetine


Name:
Duloxetine
Rx ID:
Rx00091
Validation Level:
Phenomic Similarity:
0.536
Reference ID:
DB00476
Primary Indications:
Major depressive disorder
Orphan Indications:
No annotated orphan indications.
Rare Indications:
No annotated rare indications.
Common Indications:
Stress urinary incontinence; Fibromyalgia
Pathways:
Transmission across Chemical Synapses; Neuronal System; Cocaine Action Pathway; Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics; SIDS Susceptibility Pathways; Monoamine Transport; Coc ...Click to show more
Drug Interactions:
Aldesleukin; Aliskiren; Amitriptyline; Ciprofloxacin; Desipramine; Desvenlafaxine; Flecainide; Fluvoxamine; Imipramine; Isocarboxazid; ...
Click to show more...
Food Interactions:
Food does not affect maximum levels reached, but delays it (from 6 to 10 hours) and total product exposure appears to be reduced by only 10%. People taking this product who drink large amounts of alcohol are exposed to a higher risk of liver toxicity. Take without regard to meals.

Interactive 3D Model

Interactive Drug Target Network

Interactive Bipartite Drug Repurposing Graph

Rx00091
Primary Indication
Secondary Indication

Visualize Chemical Properties

Select x-axis

Select y-axis

Disease prevalence from Electronic Health Records

Click row to show all

Disease A Disease B A∩B A∩¬B B∩¬A Odds-Ratio P-Value Adjusted P-Value
major depressive disorder Fibromyalgia 1401 17760 22201 14.337 0 0.0

Shared Genetic Architectures of Disease Pairs

Click row to show all

Disease A Disease B Adjusted P-Value Shared Gene IDs
MAJOR DEPRESSIVE DISORDER FIBROMYALGIA 6.74e-22 ADRA1A, ADRB2, ADRB3, APOE, AR, BDNF, CNR1, COMT, CYP2C19, CYP2C9, CYP2D6, DRD3, DRD4, GCH1, GPX1, GRIA4, HTR2A, HTR3A, HTR3B, MAOA, MTHFR, MYT1L, NOS3, OPRM1, RGS4, SERPINE1, SLC6A3, SLC6A4, SNAP25, SOD2

Chemical, Pharmacological and Biological Annotations


ATC Code:
N06AX21
Brands:
Ariclaim; Dulane; Duzela; Xeristar; Yentreve
Categories:
No categories annotated in DrugBank
ChEBI ID:
36795
PubChem ID:
60835
KEGG Drug ID:
D01179
SMILE:
CNCC[C@H](OC1=CC=CC2=CC=CC=C12)C1=CC=CS1
InChI:
1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m0/s1
Classification:
Kingdom:
Organic Compounds
Superclass:
Benzenoids
Class:
Acenes and Derivatives
Subclass:
Naphthalenes
Indication:
For the acute and maintenance treatment of major depressive disorder (MDD), as well as acute management of generalized anxiety disorder. Also used for the management of neuropathic pain associated with diabetic peripheral neuropathy, and fi...
Click to show more...
Pharmacodynamics:
Duloxetine is in a class of medications called selective serotonin and norepinephrine reuptake inhibitors (SSNRIs) and primarily targets major depressive disorders (MDD) and stress urinary incontinence (SUI). Duloxetine is also used to trea...
Click to show more...
Description:
Duloxetine (brand names Cymbalta, Yentreve, and in parts of Europe, Xeristar or Ariclaim) is a drug which primarily targets major depressive disorder (MDD), generalized anxiety disorder (GAD), pain related to diabetic peripheral neuropathy ...
Click to show more...
Mechanism:
Duloxetine is a potent inhibitor of neuronal serotonin and norepinephrine reuptake and a less potent inhibitor of dopamine reuptake. Duloxetine has no significant affinity for dopaminergic, adrenergic, cholinergic, histaminergic, opioid, gl...
Click to show more...

Adsorption, Distribution, Metabolism, Excretion and Toxicity


Human Intestinal Absorption:
+
Blood Brain Barrier:
+
Caco-2 permeable:
+
P-glycoprotein substrate:
Substrate
P-glycoprotein inhibitor I:
Inhibitor
P-glycoprotein inhibitor II:
Non-inhibitor
Renal organic cation transporter:
Inhibitor
CYP450 2C9 substrate:
Non-inhibitor
CYP450 2D6 substrate:
Inhibitor
CYP450 2C19 substrate:
Non-inhibitor
CYP450 inhibitory promiscuity:
High CYP Inhibitory Promiscuity
Ames test:
Non AMES toxic
Carcinogenicity:
Non-carcinogens
Biodegradation:
Not ready biodegradable
Rat acute toxicity:
2.5700 LD50, mol/kg
hERG inhibition (predictor I):
Strong inhibitor
hERG inhibition (predictor II):
Inhibitor

Contact Us:
Please contact us if you have questions or comments about RepurposeDB. You can also contact us if you need help in submitting your drug repositioning investigation to RepurposeDB.


Dudley Laboratory
Department of Genetics and Genomic Sciences
Icahn Institute for Genomics and Multiscale Biology
Icahn School of Medicine at Mount Sinai
One Gustave L. Levy Place, Box 1498
Manhattan, New York City, NY
repurposedb@dudleylab.org